fda compounding glp‑1 restriction
Prescription Weight Loss Myth Exposed Can Telehealth Thrive?
Telehealth can still thrive, but it must redesign its supply chain and compliance workflow after the FDA barred bulk compounding of semaglutide, tirzepatide and liraglutide. I explain the new hurdles, practical workarounds, and what clinics can do to keep patients on GLP-1 therapy. Medical Disclaimer: This article is for informational